Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanidatamab + vinorelbine
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Zanidatamab + vinorelbine is a combination drug regimen under investigation primarily for the treatment of **HER2-positive breast cancer**. **Zanidatamab** is a bispecific monoclonal antibody that targets two distinct epitopes on the HER2 receptor, enhancing HER2 blockade and mediating immune effector functions via antibody-dependent cellular cytotoxicity and other mechanisms. **Vinorelbine** is a vinca alkaloid chemotherapeutic agent that inhibits microtubule assembly, leading to cell cycle arrest and apoptosis. This combination aims to leverage targeted HER2 inhibition and cytotoxic chemotherapy for synergistic antitumor effects, especially in patients with metastatic or previously treated HER2-positive breast cancer. Zanidatamab is developed by Jazz Pharmaceuticals and was investigated in combination with vinorelbine within phase 1 and phase 3 clinical settings[1][3][4].
- Brand names
- Kisunla
- Other names
- ZW25 + vinorelbine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on zanidatamab + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanidatamab + vinorelbine.